Jul. 21 at 12:09 PM
$ITOS Agrees to be Acquired by Concentra Biosciences for
$10.047 in Cash per Share Plus a Contingent Value Right
https://www.globenewswire.com/news-release/2025/07/21/3118625/0/en/iTeos-Therapeutics-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-10-047-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html
CVR represents the right to receive:
1) 100% of the closing net cash of ITOS in excess of
$475 million. If ITOS has
$400M in closing net cash, nothing gets distributed to CVR holders. If ITOS has
$500M in net closing cash, then
$25M will be distributed to CVR holders
2) 80% of any net proceeds received from any disposition of certain of iTeos’ product candidates that occurs within six months following the closing
